

Financial news for PTN dated on 2020-05-12: Palatin Technologies Q3 EPS \$(0.020),
Inline

Financial news for PTN dated on 2020-02-19: Palatin Technologies, Inc. Announces
First Patient Enrolled In Dry Eye Disease Phase 2 Clinical Trial With PL9643

Financial news for PTN dated on 2020-02-11: Palatin Technologies Q2 EPS \$(0.02)
Misses \$(0.01) Estimate, Sales \$20.61K Does Not Compare To \$2.48M Estimate

Financial news for PTN dated on 2020-01-21: Palatin Provides Corporate Update And
2020 Calendar Outlook

Financial news for PTN dated on 2019-11-13: Palatin Technologies Q1 EPS \$(0.02),
Inline

Financial news for PTN dated on 2019-09-12: Palatin Technologies Q4 EPS \$0.23 Up From
\$0.06 YoY, Sales \$20.6M, Same YoY

Financial news for PTN dated on 2019-09-12: Earnings Scheduled For September 12, 2019

Financial news for PTN dated on 2019-06-25: A Look At Benzinga Pro's Most-Search
Tickers For June 25, 2019

Financial news for PTN dated on 2019-06-25: Benzinga Pro's Top 10 Most-Search
Tickers For Morning of Tuesday, June 25 2019

Financial news for PTN dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for PTN dated on 2019-06-24: 40 Stocks Moving In Monday's Mid-Day
Session

Financial news for PTN dated on 2019-06-24: 5 Stocks To Watch For June 24, 2019

Financial news for PTN dated on 2019-06-24: Palatin Technolog Shares Rise 52%
Premarket; On Friday, FDA Approved NDA for Vyleesi for Treatment of Premenopausal
Women with Acquired HSDD

Financial news for PTN dated on 2019-06-22: The Week Ahead In Biotech: Conferences,
PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for PTN dated on 2019-06-06: Palatin Technologies Reports Granted FDA
Orphan Drug Designation For PL-8177 For Treatment Of Non-Infectious Uveitis

Financial news for PTN dated on 2019-06-04: Palatin Technologies shares are trading
higher after reports surfaced that the company won Orphan Drug Designation from the
FDA for its Anterior Uveitis Treatment.

Financial news for PTN dated on 2019-06-04: Palatin Therapeutics Shares Up 10.5%
After Hours As Hearing Co. Won Orphan Drug Designation From FDA For Its Anterior
Uveitis Treatment

Financial news for PTN dated on 2019-05-09: Palatin Technologies Q3 EPS \$(0.03),
Inline

Financial news for PTN dated on 2019-04-05: 52 Biggest Movers From Yesterday

Financial news for PTN dated on 2019-04-04: 44 Stocks Moving In Thursday's Mid-Day
Session

Financial news for PTN dated on 2019-04-04: 32 Stocks Moving In Thursday's Pre-Market
Session

Financial news for PTN dated on 2019-04-04: Palatin Technologies Reports Top-Line
Results Of PL-8177 Study For Ulcerative Colitis, Other Inflammatory Bowel Diseases:
Study Met All Primary, Secondary Endpoints

Financial news for PTN dated on 2019-02-12: Palatin Technologies Q2 EPS \$(0.02) Beats
\$(0.03) Estimate

Financial news for PTN dated on 2019-01-07: Palatin Technologies Says the FDA Has
Extended the Prescription Drug User Fee Act Date for Vyleesi

Financial news for PTN dated on 2018-12-30: The Week Ahead In Biotech: Conferences,
PDUFA Dates And Clinical Trials

Financial news for PTN dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts
To Year-End Clinical Trial Results

Financial news for PTN dated on 2018-11-28: Stocks Which Set New 52-Week Low

Yesterday Tues., Nov. 27, 2018

Financial news for PTN dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for PTN dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for PTN dated on 2018-11-13: Palatin Technologies, Inc. Q1 EPS \$(0.03) Down From \$0.05 YoY, Sales \$34.505K Miss \$1.32M Estimate

Financial news for PTN dated on 2018-11-08: Palatin Technologies Reports First-In-Human Study Results Of Subcutaneous Administration Of PL-8177

Financial news for PTN dated on 2018-10-25: Seeing Sharp Spike In Palatin Technologies Following Bullish Blog Post Concerning One Of The Company's Drugs

Financial news for PTN dated on 2018-09-13: Palatin Technologies Q4 EPS \$0.06 Down From \$0.07 YoY, Sales \$20.6M Beat \$8.68M Estimate

Financial news for PTN dated on 2018-09-13: Earnings Scheduled For September 13, 2018

Financial news for PTN dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for PTN dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for PTN dated on 2018-06-27: Benzinga's Top Upgrades, Downgrades For June 27, 2018

Financial news for PTN dated on 2018-06-27: Ladenburg Thalmann Initiates Coverage On Palatin Technologies, Inc. Common Stock with Buy Rating, Announces \$3 Price Target

Financial news for PTN dated on 2018-06-08: Palatin Technologies Shares Fall Sharply Over Last Min., Now Down 10.2% For Session; Stock Rebounded At Exactly \$1 Level; Not Seeing Near-Term News To Justify Move Lower

Financial news for PTN dated on 2018-06-04: Palatin Technologies Announces FDA Acceptance to Review its NDA for Bremelanotide

Financial news for PTN dated on 2018-05-15: Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

Financial news for PTN dated on 2018-05-15: Palatin Technologies Q3 Made \$8.963M Sales

Financial news for PTN dated on 2018-04-06: HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold

Financial news for PTN dated on 2018-04-06: Palatin Technologies Shares Up 5.8% After H.C. Wainwright Earlier Initiated Stock With Buy Rating And \$5 Price Target

Financial news for PTN dated on 2018-04-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PTN dated on 2018-04-06: Benzinga's Top Upgrades, Downgrades For April 6, 2018

Financial news for PTN dated on 2018-04-06: H.C. Wainwright Initiates Coverage On Palatin Technologies, Inc. Common Stock with Buy Rating, Announces \$5.00 Price Target

Financial news for PTN dated on 2018-03-26: Palatin Technologies Submits an NDA for Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Financial news for PTN dated on 2018-02-12: Palatin Technologies Reports Q2 EPS \$0.01 vs \$0.00 Est., Sales \$10.6M

Financial news for PTN dated on 2018-02-05: Palatin Technologies, Inc. Begins Subject Dosing in First-in-Human Clinical Study of PL-8177

Financial news for PTN dated on 2018-01-03: Palatin Technologies Announces FDA Clearance of Investigational New Drug Application for PL-8177 For Ulcerative Colitis

Financial news for PTN dated on 2017-11-21: UPDATE: Palatin Technologies Will Receive \$500K Upfront Payment From Kwangdong Pharma, Eligible For Up To \$3M In First Commercial Sale in Korea, Up to \$37.5M In Sales Related Milestones Plus Royalties On Net Sales

Financial news for PTN dated on 2017-11-21: Palatin Technologies Reports Signing Of Licensing Deal With Kwangdong Pharma For Republic Of Korea

Financial news for PTN dated on 2017-11-14: 13F Filing From Baker Bros Shows New Stake In GW Pharmaceuticals, Slight Increase To Ignyta Stake, Exited Stake In Palatin Technologies and Zogenix

Financial news for PTN dated on 2017-11-13: Palatin Technologies Reports Q1 EPS \$0.05, Sales \$26.94M vs \$23.50M Est.

Financial news for PTN dated on 2017-11-13: Earnings Scheduled For November 13, 2017

Financial news for PTN dated on 2017-09-25: Palatin Technologies FY 2017 EPS \$(0.07) vs \$(0.33) Est., Sales \$44.72M vs \$20.11M Est.

Financial news for PTN dated on 2017-09-25: Earnings Scheduled For September 22, 2017

Financial news for PTN dated on 2017-09-06: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for PTN dated on 2017-09-06: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTN dated on 2017-09-06: Palatin Technologies Announces Licensing Agreement with Fosun Pharma, Palatin to Receive an Upfront \$5M Payment

Financial news for PTN dated on 2017-05-16: Palatin Technologies Q3 EPS \$(0.02) vs \$(0.08) YoY, Sales \$10.82M

Financial news for PTN dated on 2017-05-16: Earnings Scheduled For May 16, 2017

Financial news for PTN dated on 2017-02-09: Palatin Technologies Reports Q2 EPS \$(0.06) vs \$(0.07) in Same Qtr. Last Year, Sales \$403M

Financial news for PTN dated on 2017-02-03: Palatin Tech Licenses Right to Develop Rekynda to AMAG Pharma for Initial Payment of \$60M

Financial news for PTN dated on 2017-01-09: Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide

Financial news for PTN dated on 2017-01-09: AMAG Pharmaceuticals Tanks After Raymond James Downgrade

Financial news for PTN dated on 2017-01-09: UPDATE: AMAG Pharmaceuticals, Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm

Financial news for PTN dated on 2016-12-01: 12 Biggest Mid-Day Losers For Thursday

Financial news for PTN dated on 2016-12-01: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTN dated on 2016-12-01: Palatin Technologies Prices 25.38M Shares For \$16.5M In Gross Proceeds

Financial news for PTN dated on 2016-11-30: Palatin Technologies Announces Offering Of Common Stock And Warrants

Financial news for PTN dated on 2016-11-15: Palatin Technologies Reprots Q1 EP S\$(0.08) vs. Est. \$(0.08)

Financial news for PTN dated on 2016-11-03: Palatin's Female Arousal Drug Data Impresses, Investors React Positively

Financial news for PTN dated on 2016-11-02: Noble Financial Maintains Buy On Palatin Technologies, Believes Positive BMT Result Could Garner Interest For A Partnership, Maintains \$4 PT

Financial news for PTN dated on 2016-11-02: TheStreet's Adam Feuerstein Recently Publishes Series of Tweets Downplaying/Throwing Cold Water on Reuters Report of Palatin Takeover Offer

Financial news for PTN dated on 2016-11-02: Palatin Technologies Explores Potential Sale -Reuters

Financial news for PTN dated on 2016-11-01: Palatin Technologies Spikes 1117% After Hours to \$1.09 as Female Sexual Desire Drug Bremelanotide Meets Goals Of Phase III Trials

Financial news for PTN dated on 2016-09-20: Palatin Technologies Reports Q4 EPS

\$(0.09) vs. Est. \$(0.06)

Financial news for PTN dated on 2016-09-20: Earnings Scheduled For September 20, 2016

Financial news for PTN dated on 2016-06-06: Palatin Technologies Reports Received Patent Strengthening Its Melanocortin Peptide IP

Financial news for PTN dated on 2016-05-26: Palatin Technologies Reports Received Patent Strengthening Melanocortin Peptide IP

Financial news for PTN dated on 2016-05-17: Palatin Technologies Reports Q3 EPS \$(0.08) vs. Est. \$(0.08)

Financial news for PTN dated on 2016-05-17: Earnings Scheduled For May 17, 2016

Financial news for PTN dated on 2016-02-16: Palatin Technologies Reports Q2 EPS \$(0.08) vs \$(0.07) Est.

Financial news for PTN dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for PTN dated on 2015-12-10: Palatin Technologies Hits Target Patient Enrollment in Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction

Financial news for PTN dated on 2015-11-12: Palatin Tech Reports Q1 EPS \$(0.08), Inline

Financial news for PTN dated on 2015-09-21: Palatin Tech Reports Q4 Loss of \$0.09/Share vs Loss of \$0.06/Share Est.

Financial news for PTN dated on 2015-09-21: Palatin Technologies, Richter Terminate Bremelanotide License Agreement For Female Sexual Dysfunction

Financial news for PTN dated on 2015-09-21: Earnings Scheduled For September 21, 2015

Financial news for PTN dated on 2015-08-20: Palatin Technologies Shares +39% Premarket Following Wall Street Journal Report Valeant Could Acquire Sprout Pharmaceuticals for \$1B

Financial news for PTN dated on 2015-08-20: Valeant Pharmaceuticals Near \$1B Acquisition of Sprout Pharmaceuticals, According to Source -Wall Street Journal

Financial news for PTN dated on 2015-08-19: Palatin Technologies +45% Premarket Following Announcement of FDA Approval of Sprout Pharmaceuticals' Treatment for Sexual Dysfunction Flibanserin

Financial news for PTN dated on 2015-08-18: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction

Financial news for PTN dated on 2015-08-18: Palatin Shares Rise 30% After-Hours as FDA Approves Sprout Pharmaceuticals' Flibanserin

Financial news for PTN dated on 2015-08-18: FDA Approves Addyi, First Treatment for Sexual Desire Disorder, to Treat Premenopausal Women

Financial news for PTN dated on 2015-07-09: Morgan Stanley Calls Bottom In Oil Services

Financial news for PTN dated on 2015-07-06: Palatin Technologies Announces Closing of \$30M Private Placement

Financial news for PTN dated on 2015-06-16: Worst Performing Industries For June 16, 2015

Financial news for PTN dated on 2015-06-08: Palatin Technologies Continues To Post Gains, Up ~17% Monday, As Women's Viagra (Bremelanotide) Receives Marketing License

Financial news for PTN dated on 2015-06-07: Why Palatin Is Still A Buy

Financial news for PTN dated on 2015-06-05: Roth Capital: Palatin Technologies Still A Buy, Worth \$4/Share

Financial news for PTN dated on 2015-06-05: Morning Market Gainers

Financial news for PTN dated on 2015-06-05: Benzinga's Top #PreMarket Gainers

Financial news for PTN dated on 2015-06-04: Palatin Backs FDA Advisory Committee's Recommendation To Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder In Women

Financial news for PTN dated on 2015-05-13: Palatin Tech Reports Q3 Loss of \$0.07/Share vs Loss of \$0.06/Share Est.

Financial news for PTN dated on 2015-03-02: Canaccord Genuity Initiates Coverage on Palatin Technologies at Buy, Announces \$4.00 PT

Financial news for PTN dated on 2015-02-13: Palatin Tech Reports Q2 EPS 0.03 Vs Est \$0.01, Revs \$8.02M Vs Est \$54.41M

Financial news for PTN dated on 2015-02-13: Earnings Scheduled For February 13, 2015

Financial news for PTN dated on 2014-12-29: Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction

Financial news for PTN dated on 2014-11-18: Earnings Scheduled For November 18, 2014

Financial news for PTN dated on 2014-09-29: S-1 from Palatin Technologies Shows Registration to Sell Up to \$57.5M in Shares

Financial news for PTN dated on 2014-09-09: Palatin Technologies, Inc. Reports Q4 EPS of \$(0.04) vs \$0.03 Est

Financial news for PTN dated on 2014-09-09: Earnings Scheduled For September 9, 2014

Financial news for PTN dated on 2014-07-09: Palatin Technologies Announces Notification of Patent Allowance on Melanocortin Receptor-1 Specific Peptides

Financial news for PTN dated on 2014-05-13: Palatin Technologies, Inc. Reports Q3 EPS of \$(0.01) vs \$(0.03) Est

Financial news for PTN dated on 2014-02-24: UPDATE: Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

Financial news for PTN dated on 2014-02-24: Palatin Tech Reports New Data Shows Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder

Financial news for PTN dated on 2014-02-18: Palatin Technologies, Inc. Reports Q2 EPS of \$(0.03) vs \$0.03 Est

Financial news for PTN dated on 2014-01-23: Palatin Technologies Receives \$1.85M from Sale of New Jersey Tax Credits

Financial news for PTN dated on 2014-01-13: Palatin Technologies Contacted by NYSE Regarding Market Activity

Financial news for PTN dated on 2013-09-30: Palatin Technologies, Inc. Reports Q4 EPS of \$(0.04) vs \$(0.05) Est

Financial news for PTN dated on 2013-09-30: Earnings Scheduled For September 30, 2013

Financial news for PTN dated on 2013-06-21: UPDATE: Piper Jaffray Initiates Palatin Technologies at Overweight Following End of BMT Testing

Financial news for PTN dated on 2013-06-20: Piper Jaffray Initiates Coverage on Palatin Technologies, Inc. at Overweight, Announces \$2.00 PT

Financial news for PTN dated on 2013-05-14: Palatin Technologies, Inc. Reports Q3 EPS of \$(0.04) vs \$(0.06) Est

Financial news for PTN dated on 2013-05-14: Earnings Scheduled For May 14, 2013

Financial news for PTN dated on 2013-03-19: Palatin Tech Announces USPTO Issued Notice of Allowance for Patent App 13/472,914

Financial news for PTN dated on 2013-03-01: A Peek Into The Market Before The Trading Starts

Financial news for PTN dated on 2013-03-01: Palatin Technologies Announces Positive Data for Bremelanotide in Female Sexual Dysfunction

Financial news for PTN dated on 2013-02-14: Palatin Technologies, Inc. Reports Q2 EPS of \$(0.02) vs \$0.01 Est

Financial news for PTN dated on 2012-11-14: Palatin Technologies Reports Q1 EPS \$-0.15 vs \$-0.16 Est

Financial news for PTN dated on 2012-11-08: Benzinga's Microcap Movers for Thursday

November 8, 2012

Financial news for PTN dated on 2012-11-08: Palatin Technologies Reports Positive Phase 2B Results for Bremelanotide in Female Sexual Dysfunction Trial

Financial news for PTN dated on 2012-09-11: Earnings Scheduled For September 11, 2012

Financial news for PTN dated on 2012-07-06: Benzinga's Microcap Movers for Friday July 6, 2012

Financial news for PTN dated on 2012-07-02: Palatin Technologies Announces Pricing of \$35 Million Private Placement of Common Stock and Warrants

Financial news for PTN dated on 2012-06-19: Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration

Financial news for PTN dated on 2012-04-19: Palatin Technologies Announces First Patient Dosed in Second Phase I Clinical Trial of Obesity Compound from Research Collaboration

Financial news for PTN dated on 2012-03-08: Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial

Financial news for PTN dated on 2012-01-17: Palatin Technologies Receives \$1.1M From Sale of New Jersey State Tax Credits

Financial news for PTN dated on 2011-08-04: Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca

Financial news for PTN dated on 2011-06-28: Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction

Financial news for PTN dated on 2011-06-21: Palatin Technologies Issued U.S. Patent for Key Component in PL-3994 Drug Candidate

Financial news for PTN dated on 2011-03-03: Palatin Technologies CEO Buys 50,000 Shares of PTN

Financial news for PTN dated on 2011-03-03: FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma

Financial news for PTN dated on 2011-02-23: Palatin Technologies, Inc. Announces Proposed Offering of Common Stock and Warrants

Financial news for PTN dated on 2011-02-15: Palatin Technologies, Inc. Reports Q2 EPS of \$(0.09)

Financial news for PTN dated on 2010-12-02: Palatin Technologies Receives Non-Compliance Letter from NYSE Amex

Financial news for PTN dated on 2010-11-15: Palatin Technologies, Inc. Reports First Quarter 2011 EPS of \$(0.39)

Financial news for PTN dated on 2010-09-24: Palatin Announces Strategic Realignment of Operations

Financial news for PTN dated on 2010-04-19: Top 5 Stocks In The Healthcare Sector With Highest ROE (VRX, TLCR, HLF, USNA, PTN)

Financial news for PTN dated on 2009-10-01: Today's Morning Top Gainers (CHTP,XRTX,PTN,XJT,ATV)